EF Hutton Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Hoth Therapeutics (NASDAQ:HOTH) and maintained a price target of $5.
September 05, 2024 | 7:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Hoth Therapeutics and maintained a price target of $5, indicating confidence in the company's potential for growth.
The reaffirmation of a Buy rating and a $5 price target by EF Hutton suggests positive sentiment and potential upside for Hoth Therapeutics. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100